WO1991011194A1 - Lfa-3 utilise comme adjuvant de vaccins - Google Patents

Lfa-3 utilise comme adjuvant de vaccins Download PDF

Info

Publication number
WO1991011194A1
WO1991011194A1 PCT/US1991/000508 US9100508W WO9111194A1 WO 1991011194 A1 WO1991011194 A1 WO 1991011194A1 US 9100508 W US9100508 W US 9100508W WO 9111194 A1 WO9111194 A1 WO 9111194A1
Authority
WO
WIPO (PCT)
Prior art keywords
lfa
tll
vaccine
adjuvant
hepatitis
Prior art date
Application number
PCT/US1991/000508
Other languages
English (en)
Inventor
Barbara P. Wallner
David W. Thomas
Mary A. V. Crimmins
Christopher D. Benjamin
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of WO1991011194A1 publication Critical patent/WO1991011194A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • LFA-3 lymphocyte function associated antigen-3
  • This invention relates to the use of lymphocyte function associated antigen-3 (LFA-3) as an adjuvant in a vaccine mixture.
  • LFA-3 is capable of augmenting T-lymphocyte proliferation and thus enhancing the immune response to a vaccine's immunogenic component.
  • the immune system has evolved primarily to combat infection by pathogenic organisms. To accomplish this, the immune system has highly specialized effector components and complex regulatory mechanisms. The immune response is not confined to a single site in the body; effector cells move within and among lymphoid organs and various body compartments. On a cellular level, the immune, response to a pathogen depends on a complex system of communication between the various cell types of. the immune system. The mechanism of this communication among the various cells may be either by direct cell-to-cell contact or by soluble secreted mediators (cyto ines) which can act at a distance from the cell that secretes them.
  • cyto ines soluble secreted mediators
  • T cells play a central role in both types of responses (1) by interacting directly with target Gells in the production of cytotoxic T cell-mediated responses and (2) by interacting with antigen- presenting cells (APCs) bearing foreign macromolecules in the initiation of antibody responses.
  • APCs antigen- presenting cells
  • the B cells are activated to plasma cells which secrete antibodies of pre-determined specificity.
  • helper T cells plays a unique role in increasing the specificity of the B cell antibody response and in the development of "memory" B cells, which are critical for anamnestic or secondary responses to a renewed challenge by a foreign antigen.
  • T cells with target and antigen-presenting cells is highly specific and depends on the recognition of a surface antigen on the target cell or APC (or B cell) by highly specific receptors on the T cells. This interaction may be facilitated by other antigens expressed on the surface of the interacting cells, e.g., the antigen receptor complex known as CD3 on T cells or other T cell accessory molecules such as CD4, LFA-1, CD8 and CD2, and accessory molecules such as LFA-3, ICAM-1 and MHC on antigen-presenting cells. Interaction between accessory molecules on T-lymphocytes and accessory molecules on target cells or APCs (or B cells) may be important in mediating intercellular adhesion and are thought to enhance the efficiency of lymphocyte/APC and lymphocyte/target cell interactions.
  • Classical vaccine compositions are designed to activate the immune system in order to confer immunity, prophylactically, to subsequent challenges from a living pathogen that might infect and debilitate an individual or animal.
  • Vaccines generally contain two main components. The first is an immunogen which the host's immune system will recognize as foreign (not self) .
  • the immunogen is usually an attenuated viral or bacterial pathogen or proteins or polypeptides derived from the pathogen.
  • the second component is an adjuvant.
  • Classical adjuvants have ranged from simple metal salts, e.g., Al(OH) 3 (known as Alum), to complex emulsified mixtures such as Freund's adjuvant, a water- in-oil emulsion containing suspended tubercle bacilli.
  • One aspect of this invention is a composition comprising LFA-3 and an immunogen to form a vaccine mixture. Both the adjuvant and the immunogen are present in amounts sufficient to stimulate and augment the immune response in a host animal toward the immunogen.
  • Another aspect of this invention is a method of vaccination comprising administration of an LFA-3 adjuvant/immunogen mixture to a host animal.
  • a particularly preferred embodiment of the present invention is a vaccine comprising an immunogen and LFA-3 as an adjuvant, and also a co- - adjuvant comprising a ligand or an antibody recognizing other T-cell surface molecules than CD2 (e.g., CD3) , or the same or a different epitope of CD2 than that bound by LFA-3 (i.e.. Til.).
  • a co- - adjuvant comprising a ligand or an antibody recognizing other T-cell surface molecules than CD2 (e.g., CD3) , or the same or a different epitope of CD2 than that bound by LFA-3 (i.e... Til.).
  • Examples of antibodies recognizing one of the epitopes of CD2 include anti- Tll ⁇ anti-Tll 2 or anti-Tll 3 , 9.6, CD2.1, 9-1, 35.1, D66, and GT2.
  • the compositions and methods of . the present invention substantially avoid irritationi and inflammation at the site of administration as well as toxic side
  • Figure 1 is a graph showing levels of immunoglobulin secretion by monocyte-depleted human peripheral blood lymphocytes (PBLs) subjected to different stimuli.
  • the lymphocytes were cultured for 7 days in the presence of a fixed amount of anti-Til alone, different concentrations of PI-LFA-3 alone, or a combination of a fixed amount of anti-Tll 2 and different concentrations of PI-LFA-3.
  • LFA-3 Any source and form of LFA-3 is suitable provided that the LFA-3 employed is compatible with the host animal.
  • human LFA-3 should be used as the adjuvant in vaccines according to this invention intended for use in humans.
  • this invention contemplates cross-species use of LFA-3 where cross- reactivity is observed without adverse side effects.
  • primate LFA-3 is determined to be active in humans and does not have any serious side- effects, this cross-species use is within the concept of the invention.
  • the form of LFA-3 employed should itself be of limited toxicity or immunogenicity to the host.
  • the LFA-3 is either the complete • LFA-3 molecule or a fragment capable of binding to CD2.
  • the LFA-3 will be the form having a carboxyterminal phophatidylinositol linkage (PI-LFA- 3), discussed completely in copending, commonly assigned U.S. application Ser. No. 237,309, filed August 26, 1988, incorporated herein by reference. Even more preferably, the LFA-3 will be in multimeric micellar form. Most preferably, the LFA-3 is PI-LFA-3 in an octameric, micellar form. The LFA-3 may be in any form that leads to a sufficiently high binding affinity which, in turn, enhances activated T-lymphocyte proliferation or leads to crosslinking of receptor sites on the T-lymphocyte cell surface.
  • PI-LFA- 3 carboxyterminal phophatidylinositol linkage
  • LFA-3 Minor variations of the primary amino acid sequence of LFA-3 may occur and are within the scope of this invention, so long as the derivative LFA-3 binds to the CD2 receptor.
  • amino acid site- specific mutations, non-naturally-occurring amino acids, peptide structural analogs or phosphoinositol analogs may be used to augment the LFA-3 or to replace a portion of the LFA-3 molecule.
  • Soluble forms of LFA-3 may also be used. These modifications may be used to improve the biological stability of the LFA-3 adjuvant or to alter the structure of LFA-3 micelles formed from LFA-3 molecules. For example, a different hydrophobic moiety may be used to replace the carboxyr. terminal phosphoinositol appendage of PI-LFA-3.
  • an LFA-3 derivative having a hydrophobic moiety attached to the LFA-3, preferably at its carboxy-terminal end, may form a multivalent micelle.
  • the stoichiometry of such micelles will depend upon the hydrophobic moiety used as well as the particular LFA-3 derivative.
  • Suitable alternative hydrophobic moieties include, e.g., phosphatidylethanolamine.
  • the LFA-3 may be in the form of conjugates, such as fusion proteins, coupled proteins and immunoconjugates.
  • the LFA-3 may be expressed as a fusion protein linked to an immunogen, a co-adjuvant, or a protein sequence which causes aggregation of LFA- 3, e.g., domains of C4 binding protein or the amino acid sequence of gelsolin which binds to phosphoinositol.
  • LFA-3 may be chemically coupled in known ways directly to an immunogen, providing a single molecule with dual functionality with respect to the immune system.
  • LFA-3 linked to an immunogen by recombinant or chemical techniques would be expected to significantly enhance the antibody response to that immunogen by stimulating a productive cell-to-cell interaction between an immunogen-specific B cell and any T cell stimulated by the LFA-3 linked to that immunogen.
  • the LFA-3 may also be in the form of an immunoconjugate when coupled to antibodies, e.g., where anti-Til. or anti-CD3 antibodies are coupled with LFA- 3. Mixtures of LFA-3 conjugates may also be used. Regardless of the structure used, the LFA-3 should survive .in vivo for a sufficient time to augment lymphocyte activation.
  • LFA-3 may be obtained in substantially pure form from either native or recombinant sources.
  • the PI-LFA-3 may be isolated, purified, and converted to micellar form following methods described above (Springer, 1989) . A selection may be made among commonly used isolation and purification procedures without departing from the scope of this invention. Plasmids bearing genes coding for recombinant LFA-3 and recombinant Pi-linked LFA-3 have been deposited with In Vitro International under the terms of the Budapest Treaty, under accession nos. IVI-10133 and IVI-10180.
  • the immunogen may be any biological system capable of eliciting an immune response against the immunogen.
  • the immunogen may be derived from either natural, recombinant, or synthetic sources or mixtures thereof; furthermore, it may be used in substantially pure form or it may be a crude mixture of biomolecules.
  • Immunogens may be derived from viral or bacterial sources.
  • immunogens may be derived from agents responsible for acne vulgaris, caries, cholera, gonorrhea, haemophilus, klebsiella, lactobacillus, leprosy, measles, meningitis, otitis media, pertussis, rubella, syphilis, shigella, malaria, hoof and mouth disease, adenovirus, AIDS, HTLV, CMV, dengue, GBV, herpes simplex, hepatitis A, hepatitis B, hepatitis non A-non B, hepatitis C, influenza, lassa fever, parainfluenza, pneumonia, parvovirus, rotavirus, or RSV.
  • the amounts of the adjuvant and immunogen needed to evoke an immune response in the host are interrelated, but are within the ranges generally employed in conventional vaccines.
  • the preferred amount of adjuvant is between about 0.05 microgram and about 5.0 milligrams per dose. More preferably, between about 0.8 microgram and about 2.0 milligrams is used.
  • the preferred amount of immunogen is between about 0.05 microgram and about 5 milligrams per dose. More preferably, between about 0.8 micrograms and about 2 milligrams of the immunogen is used.
  • the dosage will depend upon the host receiving the vaccine as well as its size, weight, metabolism, etc. Higher doses of the immunogen may produce side effects such as chills, fever, and the like. Higher doses of the immunogen are within the scope of this invention should the clinical advantage outweigh these side effects.
  • compositions of this invention may be formulated using methods and compositions similar to those used for other pharmaceutically important polypeptides.
  • the adjuvant and immunogen may be stored in lyophilized form and reconstituted in a physiologically acceptable vehicle prior to administration.
  • the adjuvant and immunogen may be stored in the vehicle.
  • Preferred vehicles are sterile solutions.
  • Preferred vehicles include sterile buffer solutions, such as phosphate buffered saline. Any method of combining the adjuvant and the immunogen in the vehicle that retains the immunoreactivity of the mixture is appropriate.
  • the vehicle may contain preservatives or other known additives which are used to improve the. shelf stability or the efficacy of the mixture. Suitable preservatives include e.g., thimerosal.
  • the vaccine mixture also may contain additional materials that supplement the ability of LFA-3 to stimulate lymphocyte activation. For example, the combination of LFA-3 and a co-adjuvant reactive with surface molecules of T-lymphocytes (or other cells) may be used. The immune system of a host is stimulated and reacts against the vaccine of this invention very rapidly. Thus, a vaccine mixture containing LFA-3 and optionally a co-adjuvant may be used in a therapeutic manner.
  • Suitable co-adjuvants may be other surface molecules of cells involved in the immune response or fragments thereof that recognize such molecules, antibodies to such cell surface molecules (including r V and F v antibody fragments that bind to surface antigens) or mixtures thereof.
  • these additional materials are antibodies which recognize T-cell surface molecules, most preferably antibodies which recognize the same or a different epitope of CD2 than recognized by LFA-3.
  • the co-adjuvant will be an antibody recognizing the Tllj epitope, the same CD2 epitope recognized by LFA-3 (e.g., anti-Til !
  • the volume of a single dose of the vaccine of this invention may vary but will be generally within the ranges commonly employed in conventional vaccines.
  • the volume of a single dose is preferably between about 0.1 ml and about 1.0 ml, more preferably between about 0.2 ml and about 0.5 ml.
  • the adjuvan /immunogen mixture may be administered by any convenient means.
  • Preferred methods of administration include subcutaneous, intraperitoneal, intramuscular, or intravenous injection.
  • the mixture may be released from a biodiffusible implant.
  • a single administration may be used, or preferably a series of administrations may be made over the course of several days or weeks.
  • the following examples are intended to illustrate the invention but are not to be construed as limiting the same.
  • Multimeric PI-LFA-3 was isolated in the following manner. CHO cells, transfected with LFA-3 cDNA coding for the phosphoinositol linked form of LFA-3 (PI-LFA-3) were grown on collagen beads in roller bottles to 1.2 x 10 7 cells/ml. 150 ml of cell coated beads in DMEM medium were treated with 50 g collagenase for 30 min at 37 ⁇ C. Cells were pelleted, washed 2 times in 100 ml conditioned medium, then in 50 ml lx PBS, followed by 50 ml Dulbecco's medium.
  • Lymphocyte Separating Medium ORGANON TEKNIKA
  • PBLs peripheral blood lymphocytes
  • the PBLs were taken up in- RPMI-1640 (GIBCO) .
  • the growth medium was made to be 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 units penicillin G/ml growth medium, 100 micrograms streptomycin G/ml growth medium, and 5.5 x 10 ⁇ 5 M 2-mercaptoethanol.
  • the cells suspended in growth medium were placed on tissue culture treated plastic dishes (COSTAR®; Cambridge, MA) ; the cells were incubated for two cycles of 1 hr per cycle at 37°C to adhere the onocytes to the dishes. T-lymphocytes and B- lymphocytes, still suspended in solution, were removed by pipetting and transferred to the flat bottom wells of a 96-well tissue culture plate. 1 x 10 5 cells in 50 microliters growth medium were added to each well.
  • the 96 wells (all containing suspended cells) were grouped to receive phorbol myristate acetate (PMA), anti-Tll 2 (a gift of E. Reinherz, Dana-Farber Cancer Institute, Boston, MA), PI-LFA-3, various combinations of these three additives, or none of these additives (control).
  • PMA phorbol myristate acetate
  • anti-Tll 2 a gift of E. Reinherz, Dana-Farber Cancer Institute, Boston, MA
  • PI-LFA-3 various combinations of these three additives, or none of these additives (control).
  • an equal number of wells comprised, in addition to the cells, no additive (control), PMA, anti-Tll 2 , PI-LFA-3, PMA and anti-Tll 2 , PMA and PI-LFA-3, PI-LFA-3 and anti-Tll 2 , and PMA, anti- Tll 2 and PI-LFA-3.
  • a stock solution of phorbol myristate acetate (PMA) in growth medium was added so that the final concentration of PMA in the well was 0.6 ng/ml.
  • PMA phorbol myristate acetate
  • anti-Tll 2 50 microliters of a stock solution containing anti-Tll 2 in growth medium was used to obtain a final dilution in anti- Tll 2 -containing wells of 1:1000.
  • the antibody stock solution was prepared by diluting 1:250 ascites drawn from a mouse injected intraperitoneally with a hybridoma that produces anti-Til- The ascites drawn directly contained approximately 1 mg/ml of anti-Tll 2 .
  • micellar PI-LFA-3 For wells receiving PI-LFA-3, 50 microliters of micellar PI-LFA-3 in growth medium was then added to the well. Varying concentrations of PI-LFA-3 were tested, i.e., 3 ng/ml, 30 ng/ml and 300 ng/ml.
  • the total volume of each well was 200 microliters. If PMA, anti-Tll 2 or PI-LFA-3 was omitted from a particular well, then sufficient growth medium was added to make the total volume 200 microliters.
  • the number of counts obtained from a control experiment identical to that described except that PI-LFA-3 was omitted was 2000 counts per minute.
  • PBLs were isolated as in Example 1, except that the PBLs were not incubated in tissue culture plastic treated dishes. The cells were taken up in growth medium, and 1 x 10 5 cells in 50 microliters growth medium added to each well of a 96-well U bottom tissue culture plate. Test solutions were added to specific wells in 50 microliter aliquots to give the indicated final concentration. Control wells contained medium and PBLs only. Test wells contained a combination of anti-CD2 monoclonal antibodies anti- Tll 2 and anti-Tll 3 at a final dilution of 1:900 of - ascites; or anti-Tll 2 with PI-LFA-3; or anti-Tll 3 with PI-LFA-3; or each compound individually.
  • PBLs were isolated from buffy coat cells purchased from the American Red Cross (Northeast Regional Blood Services) by the method described in Example 1. After isolation from a lymphocyte separating medium (Ficoll-Paque; Pharmacia, Piscataway, NJ) , removal of the monocytes and washing, the cells were taken up in growth medium, and 2 x 10 5 cells in 50 microliters growth medium were added to each well of a 96-well U-bottom tissue culture plate. Positive control wells received no additions (other than growth medium to compensate for volume on a like basis for additions to the test wells) .
  • a lymphocyte separating medium Ficoll-Paque; Pharmacia, Piscataway, NJ
  • Test wells in one experiment contained a constant amount of anti-Tll 2 antibody (final dilution 1:900 of ascites) alone or in combination with varying amounts of PI- LFA-3.
  • Test wells in another experiment contained a constant amount of PI-LFA-3 (10 ⁇ g/ml) alone or in combination with varying amounts of anti- Tll 2 antibody.
  • Negative control wells contained a murine myeloma immunoglobulin of an isotype identical to that of the anti-Tll 2 antibody (IgG 2a ) , either alone or in combination with PI-LFA-3 (10 ⁇ g/ml) . All additions were dissolved and/or diluted in growth medium.
  • each culture well contained 200 ⁇ l of growth medium.
  • Cells were incubated 37°C, in a 5% C0 2 atmosphere for seven days. After seven days, 100 microliters of conditioned culture medium supernatant (i.e., devoid of cells) was removed; triplicates were pooled and held at -20 ⁇ C until assayed.
  • the conditioned medium was assayed for human immunoglobulin of the G and M classes by incubating said medium on microtiter ELISA plates coated with a purified goat antibody raised to human IgG and IgM (purchased from Jackson Immunoresearch,- Malvern, PA) .
  • Human immunoglobulin present in the conditioned culture medium that bound to the goat anti- human IgG and IgM coated ELISA plates was detected with an alkaline phosphatase conjugate of goat anti-human IgG and IgM.
  • the bound enzyme was illuminated by conversion of an uncolored substrate to a colored product. Color development, which directly correlates to the amount of human Ig in the culture supernatant, was quantified on a Molecular Devices Thermomax ELISA reader at a wavelength of 405 nm.
  • Vaccine mixtures containing human LFA-3 and hepatitis B core antigen are tested to investigate the effect of LFA-3 as an adjuvant in an jLn vivo model.
  • Vaccine mixtures containing 0.01-1.0 mg micellar PI- LFA-3 and 0 * 01-1.0 mg hepatitis B core antigen (Biogen, Inc., Cambridge, MA) are injected intramuscularly into rhesus monkeys three times at monthly intervals. Control groups of rhesus monkeys are injected with PI- LFA-3 alone, hepatitis B core antigen alone and buffer alone.
  • PI-LFA-3 Adjuvant activity of PI-LFA-3 is demonstrated by either greater anti-hepatitis B core antigen antibody titers or by a more prolonged presence of such antibodies in serum from monkeys receiving both PI- LFA-3 and hepatitis B core antigen when compared to serum titers obtained from monkeys of the control groups.
  • PBLs are isolated from heparinized whole blood in a manner similar to Example 1 and proliferation of activated T-lymphocytes is assayed by culturing PBLs with 0.001-0.1 mg hepatitis B core antigen with and without PI-LFA-3 under standard tissue culture conditions in microliter tissue culture plates. Proliferation is measured by incorporation of [ 3 H]- thymidine after 3-5 days of culture as in Example 1. Evidence of adjuvant efficacy is demonstrated by augmented proliferation of T-lymphocytes from rhesus monkeys receiving core antigen and PI-LFA-3, compared against T-lymphbcyte proliferation in monkeys of the control groups.
  • Human CD2 (h-CD2) transgenic mice (a gift from Dimitri Kioussis, Mill Hill, UK) are used as a model system to determine the ability of PI-LFA-3 to augment T-lymphocyte activation in vivo. Human CD2 has been shown to transduce T-cell activation signals to murine T-cells in the same manner as to human T-cells.
  • h-CD2-transgenic mice are injected with increasing amounts of PI-LFA-3 and ovalbumin; h- CD2-transgenic mice in one control group are injected with ovalbumin alone.
  • a second group of control h- CD2-transgenic mice are injected with PI-LFA-3 alone.
  • 0.1-8 micrograms PI-LFA-3 and 0.1-100 micrograms ovalbumin in 0.1 ml sterile PBS to form increasing doses are injected subcutaneously into h-CD2- transgenic mice.
  • Control mice are injected with 0.1- 100 micrograms ovalbumin in 0.1 ml sterile PBS or with 0.1-8 micrograms PI-LFA-3 in 0.1 ml sterile PBS.
  • groups of non-transgenic (normal) mice are immunized with the same moieties listed above. After 8-14 days, to assess cellular immunity, the draining lymph nodes are removed and a single cell suspension of lymphocytes is isolated.
  • the lymphocytes are cultured in a growth medium of RPMI-1640 made to be 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 units penicillin G/ml growth medium, 100 micrograms stretomycin G/ml growth medium, and 5.5 x 10 ⁇ 5 M
  • the cells are transferred to flat bottom wells of a 96-well tissue culture plate. 2 x 10 5 cells are added to each well in 50 microliters of growth medium. The wells are grouped to receive increasing amounts of ovalbumin ranging from 0.1 microgram to 100 micrograms per milliliter, and the final volume of the wells is made to be 200 microliters.
  • the lymphocytes are incubated for 2-5 days, at which time 50 microliters of growth medium containing 1 microCurie/ml of [ 3 H]-thymidine are added to each well. The cultured lymphocytes are incubated for 6 hours more. The cells are harvested and [ 3 H]- thymidine incorporation measured as described in Example 1.
  • anti-ovalbumin antibody responses are determined using conventional ELISA techniques. Mice are bled prior to immunization and two weeks following immunization; the blood is allowed to clot and serial dilutions of the aspirated serum are assayed for anti-ovalbuim activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Vaccins comprenant un immunogène et, à titre d'adjuvant, un LFA-3 (antigène-3 associé aux fonctions lymphocytaires) ou un fragment de LFA-3 capable de se lier à la CD2, un récepteur superficiel sur des lymphocytes T. On a découvert que le LFA-3 augmente d'une façon marquée la prolifération de lymphocytes T activés, et est ainsi capable d'augmenter la réponse immunitaire. L'invention concerne également des procédés de vaccination dans lesquels on utilise le LFA-3 conjointement avec un inoculum immunogène.
PCT/US1991/000508 1990-01-24 1991-01-24 Lfa-3 utilise comme adjuvant de vaccins WO1991011194A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46914090A 1990-01-24 1990-01-24
US469,140 1990-01-24

Publications (1)

Publication Number Publication Date
WO1991011194A1 true WO1991011194A1 (fr) 1991-08-08

Family

ID=23862575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/000508 WO1991011194A1 (fr) 1990-01-24 1991-01-24 Lfa-3 utilise comme adjuvant de vaccins

Country Status (5)

Country Link
EP (1) EP0463157A4 (fr)
JP (1) JPH04506666A (fr)
AU (1) AU7300091A (fr)
CA (1) CA2049931A1 (fr)
WO (1) WO1991011194A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466806A1 (fr) * 1989-04-10 1992-01-22 Biogen, Inc. Liaison de proteines par phosphatidylinositole
EP0626447A1 (fr) * 1993-05-25 1994-11-30 Bristol-Myers Squibb Company Anticorps monoclonaux et Fv contre l'antigène CD2
WO1995024217A1 (fr) * 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Procedes de modulation de l'energie des cellules t
EP0786255A1 (fr) * 1991-10-07 1997-07-30 Biogen, Inc. Procédés d'amélioration de la tolérance des greffes allogènes ou xénogènes par administration d'une protéine liante à LFA-3 ou CD2
WO2005115436A1 (fr) * 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
US7323171B2 (en) 1991-10-07 2008-01-29 Astellas Us Llc Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
EP2197487A2 (fr) * 2007-09-04 2010-06-23 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Inactivation thermique de rotavirus
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
US8562970B2 (en) 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
WO2014025198A2 (fr) * 2012-08-09 2014-02-13 주식회사 한독 Mutant de lfa3, protéine de fusion dans laquelle des polypeptides spécifiques d'une cible sont connectés au mutant ou à la région de liaison à cd2 de lfa3, et leur utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500659A (ja) * 1988-05-04 1991-02-14 ダナ‐ファーバー・キャンサー・インスチチュート・インコーポレーテッド タンパク質ミセル
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIOSIS Eur. J. Immunol., Volume 19(4), issued 1989, B.F. BIERER, et al., "A monoclonal antibody to LFA-3 the CD2 ligand specifically immobilizes major histocompatibility complex proteins", pages 661-666. See Abstract, accession Number 88038562. *
BIOSIS, Immunogenetics, Volume 28(4), issued 1988, W.A. SEWELL, et al., "The human IFA-3 gene is located at the same chromosome band as the gene for its receptor CD2", Pages 278-282. See Abstract, accession Number 87004781. *
BIOSIS, Immunol., Volume 139(8), issued 1987. S.M. DENNING, et al., "Monoclonal antibodies to CD2 and Lymphocyte Function-Associated Antigen 3 inhibit human thymic epithelial cell-dependent mature thymocyte activation". Pages 2573-2578. See Abstract, accession Number 85004878. *
BIOSIS, J. Exp. Med., Volume 166(4), issued 1987, B.P. WALLNER, et al., "Primary Structure of Lymphocyte Function-Associated Antigen 3 LFA-3 the Ligand of the T Lymphocyte CD2 Glyco-protein". Pages 923-932. See Abstract, accession Number 85012425. *
BIOSIS, J. Immunol., Volume 138(2), issued 1987, I.W. VOLLGER, et al. "Thymocyte binding to human thymic epithelial cells in inhibited by monoclonal antibodies to CD2 and LFA-3 antigens. Pages 358-363. See Abstract, accession Number 83075839. *
BIOSIS, Philos. Trans. R. Sci. Lond. B. Biol. Sci., Volume 323. Issued 1989, M.J. CRUMPTON "T-lymphocyte Unreadable Text Page 519. See Abstract, accession Number 90075684. *
BIOSIS, Proc. Natl. Acad. Sci., Volume 84(19), issued 1987, Y. TAKAI, et al., "Direct evidence for a receptor ligand interaction between the T cell surface antigen CD2 and Lymphocyte Associated Antigen 3, Pages 6864-6868. See Abstract, accession Number 85004802. *
BIOSIS, Proc. Natl. Acad. Sci., Volume 85(4), Issued 1988, B.F. BIERER, et al., "Expression of the T-cell surface molecule CD2 and an epitope-loss CD2 mutant to define the role of lymphocyte function associated antigen 3 LFA-3 in T-cell activation", Pages 1194-1198. See Abstract, accession Number 85110876. *
Medline, Surv. Immunol. Res., Volume 3(1), issued 1984, A.M. KRENSKY, et al., "Human lymphocyte function-associated antigens". Pages 39-44. See Abstract, accession Number 84195633. *
See also references of EP0463157A4 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466806A4 (en) * 1989-04-10 1992-08-12 Biogen, Inc. Phosphatidylinositol linking of proteins
EP0466806A1 (fr) * 1989-04-10 1992-01-22 Biogen, Inc. Liaison de proteines par phosphatidylinositole
EP0786255A1 (fr) * 1991-10-07 1997-07-30 Biogen, Inc. Procédés d'amélioration de la tolérance des greffes allogènes ou xénogènes par administration d'une protéine liante à LFA-3 ou CD2
US7323171B2 (en) 1991-10-07 2008-01-29 Astellas Us Llc Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
US6384198B1 (en) 1993-05-25 2002-05-07 Bristol-Myers Sqibb Company Methods for inhibiting the production of HIV-1 retrovirus using monoclonal antibodies and Fv specific for CD2 antigen
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
US5807734A (en) * 1993-05-25 1998-09-15 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
EP0626447A1 (fr) * 1993-05-25 1994-11-30 Bristol-Myers Squibb Company Anticorps monoclonaux et Fv contre l'antigène CD2
AU709711B2 (en) * 1994-03-08 1999-09-02 Dana-Farber Cancer Institute Methods for modulating T cell unresponsiveness
EP1025856A2 (fr) * 1994-03-08 2000-08-09 Dana-Farber Cancer Institute Procédés de modulation de l'énergie des cellules T
US6451305B1 (en) 1994-03-08 2002-09-17 Dana-Farber Cancer Institute Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand
EP1025856A3 (fr) * 1994-03-08 2002-10-16 Dana-Farber Cancer Institute Procédés de modulation de l'énergie des cellules T
WO1995024217A1 (fr) * 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Procedes de modulation de l'energie des cellules t
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US8562970B2 (en) 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
US7662921B2 (en) 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
WO2005115436A1 (fr) * 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
EP2197487A2 (fr) * 2007-09-04 2010-06-23 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Inactivation thermique de rotavirus
EP2197487A4 (fr) * 2007-09-04 2012-06-13 Us Gov Health & Human Serv Inactivation thermique de rotavirus
US8357525B2 (en) 2007-09-04 2013-01-22 The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention Thermal inactivation of rotavirus
US10556001B2 (en) 2007-09-04 2020-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thermal inactivation of rotavirus
US11103572B2 (en) 2007-09-04 2021-08-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thermal inactivation of rotavirus
WO2014025198A2 (fr) * 2012-08-09 2014-02-13 주식회사 한독 Mutant de lfa3, protéine de fusion dans laquelle des polypeptides spécifiques d'une cible sont connectés au mutant ou à la région de liaison à cd2 de lfa3, et leur utilisation
WO2014025198A3 (fr) * 2012-08-09 2014-04-03 주식회사 한독 Mutant de lfa3, protéine de fusion dans laquelle des polypeptides spécifiques d'une cible sont connectés au mutant ou à la région de liaison à cd2 de lfa3, et leur utilisation

Also Published As

Publication number Publication date
EP0463157A4 (en) 1992-06-03
JPH04506666A (ja) 1992-11-19
EP0463157A1 (fr) 1992-01-02
AU7300091A (en) 1991-08-21
CA2049931A1 (fr) 1991-07-25

Similar Documents

Publication Publication Date Title
US4950480A (en) Enhancement of antigen immunogenicity
US6004763A (en) Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
JP2546544B2 (ja) 免疫強化を促進するための方法と組成物
US6248332B1 (en) Targeted immunostimulation with bispecific reagents
CA2337969C (fr) Compose et methode de prevention et/ou de traitement des allergies
KR20110036618A (ko) 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
WO1994008601A1 (fr) Amelioration de la resistance au lymphome des lymphocytes b par l'utilisation de conjugues idiotype/cytokine
WO2000000156A2 (fr) Methodes et compositions permettant de moduler les reponses immunitaires (humorales) specifiques a un antigene en ciblant ledit antigene sur des cellules presentatrices de l'antigene en conjonction avec l'administration de ligands anti-cd-40
WO1991011194A1 (fr) Lfa-3 utilise comme adjuvant de vaccins
JPH09176042A (ja) 免疫調節組成物
US7070785B2 (en) Heat shock proteins for use in enhancing cellular factor production
US20030152581A1 (en) Compound and method for the prevention and/or the treatment of allergy
Robinson et al. Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells.
EP0166548A2 (fr) Vaccin à spectre large contre la gonorrhée
Allison et al. Adjuvants for a new generation of vaccines
Wiesmüller et al. The antibody response in BALB/c mice to the Plasmodium falciparum circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant.
US5824310A (en) Lipopplysaccharide conjugate vaccines
Kramp et al. Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines
AU5485696A (en) Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
Allison Antigens and adjuvants for a new generation of vaccines
WO1996032963A9 (fr) Declenchement et renforcement de la reaction immunitaire aux polysaccharides a l'aide de lipoproteines bacteriennes
Allison The role of cytokines in the action of immunological adjuvants
WO1993019775A1 (fr) Administration de liposomes contenant des peptides ou des proteines comportant des determinants antigeniques de ctl de proteines vih
Moureau et al. Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly (DL-lactide-co-glycolide) microparticles
Allison Adjuvants for New and Improved Vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2049931

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991904441

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991904441

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991904441

Country of ref document: EP